*仅供医学专业人士阅读参考众所周知，T细胞通过主要组织相容性复合体（MHC）识别靶细胞。一直以来，我们都认为，所有细胞表面都存在的MHC-I类分子，仅调节CD8阳性T细胞和NK细胞介导的免疫反应；而只存在于抗原呈递细胞表面的MHC-II类分子，则调节 ...

The ability of immune cells-particularly CD8 + T cells-to launch a rapid burst of proliferation inside tumors is key to the success of modern day cancer immunotherapies. However, the factors and ...

In a study published in Nature Aging on Nov. 26, a research team from the Shanghai Institute of Nutrition and Health (SINH) of the Chinese Academy of Sciences revealed that aging specifically impairs ...

A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the ...

IL-2 is clinically validated as an immunotherapeutic, but its use is limited by toxicity issues. AZD-6750 is an approach from Astrazeneca plc that applies cis-guiding to deliver a modified IL-2 mutein ...

A research team from the Johns Hopkins Kimmel Cancer Center, its Bloomberg~Kimmel Institute for Cancer Immunotherapy and the ...

Cancer-fighting T cells do not simply "run out of energy." They are molecularly reprogrammed. For years, mitochondrial dysfunction has been recognized as a hallmark of exhausted T cells in tumors. Yet ...

Researchers at the Max Delbrück Center and the University of Oxford have found that a cellular housekeeping function called autophagy—by which cell components are broken down and recycled—plays a ...

Tevogen Bio announced an agreement with CD 8 Technology Services to develop a turn-key facility aimed at enhancing its in-house capabilities for pre-clinical research and GMP cell therapy production.